EUCTR2010-019785-90-BG进行中（未招募）不适用
A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumatic Neuralgia
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Male, or female of non-child bearing potential (18-80 years, inclusive). Only women of non-child bearing potential are included in the study, ie, women who are permanently or surgically sterilised or post menopasual:
- •- Women will be considered post menopausal if they are amenorrheic for 12 months without an alternative medical cause.
- •The following age-specific requirements apply:
- •- Women under 50 years old will be considered post menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range.
- •- Women over 50 years of age will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments.
- •Permanent sterilization includes hysterectomy and/or bilateral oopherectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion.
- •3. Neuropathic pain due to peripheral nerve injury caused by trauma or surgery.
- •Duration of neuropathic pain must be at least three months and at most 5 years.
- •Complex Regional Pain Syndrome (CRPS) type II is accepted provided that pain is due to a defined nerve injury. Nerve injuries at plexus or root level are excluded.
- •4. Pain intensity (7 days recall) of 4-9 (inclusive) on NRS - Average Pain (0-10) is required for enrolment. At randomisation a 5-day mean baseline NRS - Average Pain intensity (12 h recall twice daily, morning and evening) of 4-9 (inclusive) is required. The patient is also required to complete at least 4 out of 5 morning and evening baseline NRS - Average Pain assessments Day –5 to Day –1 to be eligible.
- •5. Be able to understand and comply with the requirements of the study as judged by the investigator.
- •For inclusion in the genetic research, patients must fulfil the following criterion:
- •6. Provision of informed consent for genetic research. If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study described in this CSP, so long as they consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 62
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 63
排除标准
- •1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
- •2. Previous enrolment or randomisation in the present study.
- •3. Participation in another clinical study with an IP during the last 30 days prior to enrolment.
- •4. Other pain that may confound assessment of neuropathic pain, as judged by the
- •investigator.
- •5. Central neuropathic pain conditions (caused by CNS injury/disease, eg, stroke, multiple sclerosis or spinal cord injury).
- •6. Any prior treatment of neuropathic pain with intrathecal pump or spinal cord stimulator.
- •7. History of treatment failure with =3 adequate trials of medications used to treat neuropathic pain, as judged by the investigator.
- •8. Use of any prohibited medication (see Table 4) at Visit 2.
- •9. History of any unstable medical disease (eg,, cardiovascular, renal insufficiency, hepatic insufficiency) which may interfere with the objectives of the study or with the safety of the subject, as judged by the investigator.
- •10. History of gastric ulcer or haemorrhage
- •11. History of significant psychiatric disease/disorder that could preclude reliable participation in the study, as judged by the investigator.
- •- Patients with a diagnosis of depression who are in remission for at least 12 weeks before enrolment with or without stable SSRI treatment are allowed in the study.
- •12. Patient with a cognitive disorder which could impair cooperation with study procedures, as judged by the investigator.
- •13. Clinically significant illness within 2 weeks before the administration of the IP as judged by the investigator.
- •14. Known malignancy within the past 5 years (with the exception of successfully treated basal cell carcinoma).
- •15. Malabsorption, gastrointestinal disorder or surgery leading to impaired drug absorption.
- •16. Donation of plasma from 2 weeks before Visit 1 (enrolment visit) or donation of blood from 3 months before Visit 1.
- •17. Abnormal vital signs, laboratory test value or ECG of clinical significance, as judged by the investigator.
- •- QTcF>450 ms or <340 ms, or a family history of long QT syndrome.
- •- Calculated Creatinine clearance =50 mL/min assessed by the Cockroft-Gault method.
- •- ALT or AST >1.5xULN
- •- Bilirubin > 1xULN
- •18. Positive Tuberculosis screening (i.e. chest x-ray and QuantiFERON® – TB Gold according to local requirements) as judged by investigator.
- •19. Immunisation with live vaccine within the previous 3 months, for other vaccines within the past 30 days.
- •20. History of latent, chronic, or recurrent infections (eg, tuberculosis, recurrent sinusitis, genital herpes, urinary tract infections) or at risk of infection (surgery,
- •trauma or significant infection, history of skin abscesses within 90 days prior to Visit 1).
- •21. Women with a positive pregnancy test on enrolment or before randomisation or lactating women.
- •22. History of alcohol or drug abuse within 2 years of entering the study.
- •23. Contraindication to ibuprofen/NSAIDs, such as ulcer and history of hypersensitivity reactions (eg, asthma, rhinitis or urticaria).
- •24. History of or positive test of human immunodeficiency virus (HIV) or hepatitis B or C.
- •25. Positive urine toxicology results for drugs of abuse including cannabis, cocaine, ecstacy, heroin/morphine, amphetamine and phenocyclidine (PCP). Visit 1 urine
- •toxicology results indicating opiate or other prescribed analgesic (including benzodiazepines) use in patients who had been receiving the medic
研究者
相似试验
进行中（未招募）
不适用
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgiaPosttraumatic Neuralgia (neuropathic pain)MedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019785-90-SEAstraZeneca AB135
进行中（未招募）
1 期
A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumatic NeuralgiaPosttraumatic Neuralgia (neuropathic pain)MedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2010-019785-90-FRAstraZeneca AB135
进行中（未招募）
不适用
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgiaPosttraumatic Neuralgia (neuropathic pain)MedDRA version: 14.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019785-90-GBAstraZeneca AB135
进行中（未招募）
不适用
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgiaEUCTR2010-019785-90-DKAstraZeneca AB135
进行中（未招募）
不适用
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgiaEUCTR2010-019785-90-PLAstraZeneca AB135